GSK agrees to settle about 80,000 Zantac lawsuits for up to ...
WEB3 days ago · Oct 9 (Reuters) - GSK (GSK.L) has agreed to pay up to $2.2 billion to settle most lawsuits in U.S. state courts claiming that a discontinued version of the heartburn drug Zantac caused cancer, the ...
Zantac’s Developer Settles Lawsuits Claiming Cancer Link
WEB2 days ago · Oct. 9, 2024. The British drug maker GSK said on Wednesday that it would pay up to $2.2 billion to settle most of the lawsuits filed against it by people who claim that they developed cancer after ...
GSK presents positive data for AREXVY, its respiratory ...
WEB4 days ago · GSK plc (LSE/NYSE: GSK) today announced new data from the AReSVi-006 (Adult Respiratory Syncytial Virus) phase III trial evaluating the efficacy and safety of a single dose of AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) against lower respiratory tract disease (LRTD) caused by respiratory syncytial virus …
GSK shares jump after landmark £1.68bn heartburn drug ...
WEB2 days ago · Alex Daniel 8 hours ago. Shares in drugmaker GSK surged on Thursday after it struck a 2.2 billion US dollar (£1.68 billion) settlement to resolve tens of thousands of lawsuits in the US over its ...
GSK shares jump on $2.2 billion Zantac settlement
WEB2 days ago · The recall triggered a spate of lawsuits. (Reuters) -GSK shares jumped as much as 6.5% on Thursday after the British drugmaker struck a $2.2 billion settlement over U.S. lawsuits that alleged its discontinued heartburn drug Zantac caused cancer. Barclays analysts described it as a "best case scenario in terms of aggregate settlement".
Press releases - GSK
WEBBrowse GSK global press releases issued since 2009. Search them by keyword or browse by year/business category. Press releases issued by our local operating companies can be viewed on our market websites.
Statement: Zantac (ranitidine) litigation - GSK
WEB3 days ago · 09 October 2024. Issued: London, UK. For media and investors only. Statement: Zantac (ranitidine) litigation – settlement agreements reached. Download (PDF, 130.6KB) GSK to resolve 93% (approximately 80,000 cases) of U.S. state court Zantac product liability cases for up to $2.2 billion. Separate settlement of …
GSK set to face jury trials over heartburn drug Zantac
WEBJun 1, 2024 · GSK and other pharmaceutical groups are set to face jury trials in cases brought by more than 72,000 cancer sufferers who allege a heartburn drug caused their condition, after a judge in Delaware...
GSK shares tumble after Delaware court ruling on Zantac
WEBJun 3, 2024 · GSK shares dropped almost 10 per cent on Monday after a ruling from a Delaware judge left the UK drugmaker exposed to US jury trials over its allegedly carcinogenic heartburn treatment Zantac.
GSK makes a strong start to 2024 with improving outlook for ...
WEBMay 1, 2024 · Now expect 2024 turnover growth towards the upper part of 5% to 7% range; Core operating profit growth of 9% to 11% (previously 7% to 10%); Core EPS growth of 8% to 10% (previously 6% to 9%) Dividend declared of 15p for …
- Some results have been removed